Bio-K+ International Participates In ERSP Forum
New York,NY– June 29, 2007 – The Electronic Retailing Self-Regulation Program (ERSP) has determined that Bio-K+ International (Bio-K+), has provided a reasonable basis for certain claims for the Bio-K+ CL1285 probiotics, but recommended modification of others. The marketer’s advertising was brought to the attention of ERSP by an anonymous competitor.
ERSP, the electronic direct-response industry’s self-regulatory forum, is administered by the Council of Better Business Bureaus (CBBB) with policy oversight by the National Advertising Review Council (NARC).
Claims at issue in the ERSP inquiry included:
- “Clinically proven to prevent antibiotic-associated diarrhea (AAD); C
- difficile-associated diarrhea (CDAD).”
- “The highest concentration of fresh, live bacteria with a minimum of 50 billion at consumption.”
- “A probiotic whose efficacy is medically proven.”
- “As a nutritionist and researcher, I have not seen any probiotic perform as well as Bio-K+. For consistent results, I recommend Bio-K+…because it works!”
ERSP determined that the marketer’s randomized, double-blind, placebo controlled study provided a reasonable basis for its claim that the product has been clinically tested for the prevention of AAD. However, ERSP noted, it is inaccurate to state the product is “clinically proven to prevent CDAD.”
ERSP recommended that the marketer clearly make a distinction in its advertising to clarify that only the original, 50 billion strain Bio -K+ CL1285 is the product that has been clinically proven to prevent AAD and not the other product variations in the line.
ERSP determined that the marketer provided a reasonable basis for claims of general product performance that were communicated in the advertising and found that the the marketer’s expert endorsements were appropriately communicated.
ERSP recommended the marketer include a clear and conspicuous disclosure on the consumer testimonial page to alert consumers that the testimonials are based on individual experience and that individual results may vary.
The company, in its marketer statement, said “Bio-K+ International has a long standing tradition of communicating balanced, accurate and scientifically validated information to consumers. While we feel vindicated by the above review of our advertising by the (ERSP), the report makes recommendations that we support and have every intention of implementing.”
Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.
Latest Decisions
National Advertising Division Recommends Oral Essentials Discontinue "Certified Non-Toxic" Claim for its Lumineux Mouthwash
New York, NY – December 30, 2024 – In a Fast-Track SWIFT challenge brought by GuruNanda, the National Advertising Division recommended that Oral Essentials discontinue its claim that Lumineux mouthwash products are “Certified Non-Toxic.”
NARB Recommends T-Mobile Discontinue or Modify Commercial to Better Disclose Conditions of Free iPhone Offer, 20% Savings Claim
New York, NY – December 30, 2024 – A panel of the National Advertising Review Board (NARB) recommended that T-Mobile discontinue or modify its commercial to better disclose the material conditions of its free iPhone 16 Pro offer and its 20% rate plan savings claim compared to AT&T and Verizon.
Direct Selling Self-Regulatory Council Recommends Valentus Discontinue Earnings and Product Performance Claims
McLean, VA – December 23, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended Valentus, a direct selling company that sells nutritional and lifestyle products, discontinue earnings and health-related product performance claims made on social media and on the Valentus website.
Direct Selling Self-Regulatory Council Refers Olive Tree Earnings Claims to the FTC and California AG for Possible Enforcement Action
McLean, VA – December 20, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) referred Olive Tree to the Federal Trade Commission (FTC) and California Attorney General's Office for possible enforcement action after Olive Tree failed to respond to a DSSRC inquiry into earnings claims.